Organometallic complexes as therapeutic agents

Abstract

This invention comprises salophene-based metallic complexes. Included are metal-chelating analogues, and method of their preparation and use. These analogues have therapeutic activity including anticancer activity.

1 . A compounds having the formula (I) or (II): 
       
         
           
           
               
               
           
         
         B is selected from ligands such as halides, acetate, oxalates, succinate, fumarates, tartarates. 
         Z is selected from the group consisting of C, N, O or S; 
         R is selected from the group consisting of H, amino, hydroxyl, halogens, alkyl, aryl, heteroaryl, arylalkyl, acetyl, carbamates, urea, or thiourea, alkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, OH, COOH, CHO, halide, NO 2 , or NH 2 , or said substituent further combined with at least one substituent selected from the group consisting of amide, urea, thiourea, CN, bicyclic amine, or bicyclicdiamine; 
         M is a metal; 
         Z 1  is selected from the group consisting of O, N or S. 
       
     
     
         2 . Compound I of  claim 1 . 
     
     
         3 . Compound II of  claim 1 . 
     
     
         4 . The compound I of  claim 1  having the following structure 
       
         
           
           
               
               
           
         
         Z is selected from the group consisting of C, N, O or S; and, 
         R is selected from the group consisting of H, amino, hydroxyl, halogens, alkyl, aryl, heteroaryl, arylalkyl, acetyl, carbamates, urea, or thiourea, alkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, OH, COOH, CHO, halide, NO 2 , or NH 2 , or said substituent further combined with at least one substituent selected from the group consisting of amide, urea, thiourea, CN, bicyclic amine, or bicyclicdiamine. 
       
     
     
         5 . The compound of  claim 1  and wherein one or more R substituents is further combined to form a substituent selected from the group consisting of piperazine, piperidine, peptidic bonds, alkyl, aryl, arylalkyl, fused saturated, half saturated two or four cyclic or heterocyclic rings or sugar. 
     
     
         6 . The compound of  claim 1  wherein M is a transitional metal. 
     
     
         7 . The compound of  claim 6  wherein in transitional metal is selected from the group consisting of lanthanides or actinides 
     
     
         8 . The compound of  claim 6  wherein M is rhodium or lanthanum. 
     
     
         9 . The compound of  claim 1  wherein M is Fe. 
     
     
         10 . The compound of  claim 1  wherein the structure is 
       
         
           
           
               
               
           
         
       
     
     
         11 . A method of treating a subject in need of such treatment by administering to such subject a therapeutically effective dose of a compound of  claim 1 . 
     
     
         12 . The method of  claim 11  wherein the dosage is from about 5 mg to about 5 g. 
     
     
         13 . The method of  claim 11  wherein the dosage is about 0.01 to 1000 milligram (mg) per kilogram (kg) of body weight of recipient per day. 
     
     
         14 . The method of  claim 13  wherein the dosage is about 1 to 100 mg per kg of body weight of recipient per day. 
     
     
         15 . The method of  claim 14  wherein the dosage is about 2 to 20 mg per kg of body weight of recipient per day. 
     
     
         16 . The method of  claim 11  wherein the treatment is cancer therapy. 
     
     
         17 . The method of  claim 16  wherein the cancer is selected from the group comprising ovarian, cervical, and breast cancer. 
     
     
         18 . The method of  claim 17  wherein the cancer is ovarian cancer.